Tariffs and the MFN policy are not effective responses to these problems, however. Implementing either policy would harm patients and cause distressing drug shortages and access issues. If the Administration is truly committed to helping patients, it will jettison these destructive policies.
Judged by its actions, the Trump Administration supports drug shortages.
Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Wayne Winegarden
Tariffs and the MFN policy are not effective responses to these problems, however. Implementing either policy would harm patients and cause distressing drug shortages and access issues. If the Administration is truly committed to helping patients, it will jettison these destructive policies.
Judged by its actions, the Trump Administration supports drug shortages.
Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.